Back to Test Catalogue

Ustekinumab Quantitation with Antibodies, Serum

Test ID: USQA S

Test

Aliases/Synonyms

Stelara; Stelara antibodies

Method

ELISA

Method Description

Ustekinumab (UTK) quantitation and anti-ustekinumab antibody measurements are performed using enzyme-linked immunosorbent assay. Microwell strips are pre-coated with UTK or anti-UTK antibody . Calibrators, controls, and patient samples are added to separate wells, allowing either UTK or antibodies to ustekinumab (ATUs) to bind to immobilized antigen. Unbound sample is washed away, and a second horseradish peroxidase-labeled anti-UTK or UTK (conjugate) is added to each well. A second incubation step allows the conjugate to bind to the UTK or ATU that has become attached to the microwells. After washing away the excess of unbound conjugate, the remaining enzyme activity is determined by adding a substrate and measuring the intensity of the color that develops in a spectrophotometer. The signal obtained is proportional to the amount of UTK or ATUs in the patient sample.

Report Includes

Ustekinumab; Ustekinumab Antibodies

Specimens

Serum

Clinical Utility

Evaluation of loss of response to therapy.
Quantification of ustekinumab in human serum.
Trough level quantitation for evaluation of patients treated with ustekinumab.
Detection of antibodies to ustekinumab in human serum.

Test Version

19-Nov-2025

Specimen

Specimens

Serum

Collection Containers

Preferred

Gold top (clot activator & gel)

Acceptable

Red top (no additive)

Sample Volume

0.5 mL

Minimum Volume

0.35 mL

Patient Preparation

Collect specimen immediately before the next dose of drug administration (trough level).

Collection & Handling

Handling Information

Store and send cold or frozen.

Stability

Refrigerated 21 days
Frozen 21 days

Rejection Criteria

Specimen Heat Inactivated

Test Version

19-Nov-2025

Performance / Interpretation

Method

ELISA

Method Description

Ustekinumab (UTK) quantitation and anti-ustekinumab antibody measurements are performed using enzyme-linked immunosorbent assay. Microwell strips are pre-coated with UTK or anti-UTK antibody . Calibrators, controls, and patient samples are added to separate wells, allowing either UTK or antibodies to ustekinumab (ATUs) to bind to immobilized antigen. Unbound sample is washed away, and a second horseradish peroxidase-labeled anti-UTK or UTK (conjugate) is added to each well. A second incubation step allows the conjugate to bind to the UTK or ATU that has become attached to the microwells. After washing away the excess of unbound conjugate, the remaining enzyme activity is determined by adding a substrate and measuring the intensity of the color that develops in a spectrophotometer. The signal obtained is proportional to the amount of UTK or ATUs in the patient sample.

Turnaround Time

9 days

Results

Name Units Reference Range Conversion Factor
Ustekinumab quantification mcg/mL
  • In inflammatory bowel disease, at post-induction measurement (week 8), concentrations above 3.5 mcg/mL are associated with good outcomes.
    For maintenance stages:
    Concentrations ≥ 1.0 mcg/mL are associated with clinical response and clinical remission
    Concentrations ≥ 4.5 mcg/mL are associated with mucosal healing.
Ustekinumab Antibodies AU/mL
  • Absent: <10
  • Present: ≥ 10

Test Version

19-Nov-2025

Interface / Setup

HL7 Interface Codes

Order Code Result Codes Units
USQA S 65235Ustekinumab QN, S mcg/mL
65236Ustekinumab Ab, S AU/mL

Test Version

19-Nov-2025